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Abstract
Nano erythrocyte ghosts have recently been used as drug carriers of water-soluble APIs due to inherit biological
characteristics of good compatibility, low toxicity, and small side-effect. In this study, we developed a novel drug
delivery system based on nano erythrocyte ghosts (STS-Nano-RBCs) to transport Sodium Tanshinone IIA sulfonate
(STS) for intravenous use in rat. STS-Nano-RBCs were prepared by hypotonic lysis and by extrusion methods, and its
biological properties were investigated compared with STS injection. The results revealed that STS-Nano-RBCs have
narrow particle size distribution, good drug loading efficiency, and good stability within 21 days. Compared with
STS injection, STS-Nano-RBCs extended the drug release time in vitro and in vivo with better repairing effect on
oxidative stress-impaired endothelial cells. These results suggest that the nano erythrocyte ghosts system could be
used to deliver STS.
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Background
To date, numerous nanoparticles (NPs) delivery has
been used to deliver drugs, including polymeric NPs,
liposome, microspheres, cell and cell derivatives [1]. As
potential drug delivery systems, cell and cell derivatives
have been widely researched recently, such as erythro-
cyte (RBC), tumor cell, stem cell, macrophage, dendritic
cell. [2–4]. Among them, erythrocyte widely attracted
the attention of researchers. Comparing with other cell
drug carriers, erythrocyte is easier to be separated, with
better biological compatibility as well as the inherent
biological degradation. Besides that, it also has the re-
markable long life span of about 3 months in the body
[5]. Therefore, small-molecule drugs (doxorubicin [6],
dexamethasone sodium phosphate [7]), enzyme (pegade-
mase, adenosine deaminase [8], L-Asprraginase [9]),
nucleoside (FdUMP [10], antisense oligodeoxynucleo-
tides [11]), and nanoparticles [12] have been encapsu-
lated in erythrocyte. In recent years, nanoparticles
derived from erythrocyte (Nano-RBCs), have strongly
attracted the attention of investigators due to the virtue
inherited from their parent cells. Besides that,
nanoparticles contain therapeutic molecule which could
camouflaged themselves with erythrocyte membrane to
reduce toxicity [13]. Researches revealed that polymeric
nanoparticles loaded in Nano-RBCs showed longer
circulation time in blood than PEG-medicated nanopar-
ticles [14]. Besides, coating with Nano-RBC membrane
could protect the original nanoparticle from being
uptake by macrophage [15]. 1–1.5 × 109 erythrocyte
ghosts can split into 1.6 × 1012 nanoparticles without
considering the loss of erythrocyte membrane. Nanopar-
ticles derived from erythrocyte have high surface area-
volume ratio, and its diameter can be small to 100 nm,
which helps them easily transmit in vivo [16]. The popu-
lar method of Nano-RBC preparation is using hypotonic
medium to make erythrocyte change to erythrocyte
ghost and then split to smaller vesicles with ultra-
sonic bath, finally extrude the vesicles through poly-
carbonate membrane from different pore sizes to
unified size gradually [14, 15]. Besides, tip sonicator
could also split the Nano-RBCs to around 100 nm
directly [16]. So far, a variety of nanoparticles [14, 15]
and a small-molecule weight drug (Fasudil, paclitaxel,
and doxorubicin) [17, 18] have been encapsulated into
Nano-RBC, such as vaccine encapsulated in polymeric
nanoparticles and coated with Nano-RBC was
developed to prevent the melanoma [19]. Besides, the
* Correspondence: dor_qin@163.com
1Department of Pharmaceutics, School of Pharmacy, Guangdong
Pharmaceutical University, No. 280 Waihuandong Road, Guangzhou 510006,
China
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Dong et al. Nanoscale Research Letters  (2017) 12:202 
DOI 10.1186/s11671-017-1980-5
Nano-RBC with gold nanocages was prepared to im-
prove the efficiency of the photothermal therapy [20].
Sodium tanshinone IIA sulfonate (STS, Fig. 1) has
been widely used in the treatment of cardiovascular dis-
eases with the effect of arteries expansion and blood
flow speedup [21]. Several studies also indicated that
STS had not only with pharmacological effect of anti-in-
flammatory and anti-oxidant in the recovery of tissue is-
chemia injury [22], but also with the effect of protecting
damaged vascular endothelial cells by promoting expres-
sion of vascular endothelial growth factor (VEGF) [23].
However, STS eliminates very fast in vivo. The half-life
time of STS injected intravenously is less than 0.9 h and
95% drug eliminate in blood within 4 h [24, 25]. To over-
come this, numerous dosage forms are applied to achieve
longer systemic circulation and better efficacy [24].
In present study, we developed a novel STS-loaded
nano-erythrocyte system which was extracted from
Sprague dowley (SD) rats. The influence factors of prep-
aration process were investigated to optimize the manu-
facture process. The stability was tested with the index
of particle size and loading efficiency. In vitro and in
vivo release behaviors were analyzed to predict its
pharmacological effect. Since STS has a protecting func-
tion against the oxidative stress induced injury [25], an
oxidative stress-impaired model was established with
EA.hy926 endothelial cells to assess the repair efficiency
of STS-Nano-RBCs and STS injection.
Methods
Materials
STS, heparin sodium, 30% hydrogen peroxide solution
(H2O2, 30 wt.% in water), ethyl p-hydroxybenzoate,
acetonitrile, and DMSO were made by Aladdin (Shang-
hai, China). Red blood cell lysis buffer, kaumas blue, cell
lysis buffer for western and IP, Nitric Oxide Assay Kit,
Total Superoxide Dismutase Assay Kit with WST-8,
Lipid Peroxidation MDA Assay Kit, and Reactive Oxy-
gen Species Assay Kit were purchased from Beyotime
Biotechnology (Shanghai, China). Amicon Ultra-4 Cen-
trifugal Filter (30 kDa) and Nuclepore Track-Etched
Membrane were purchased from Millipore (Boston,
USA). 0.5% Triton X-100, 3-(4,5-dimethylthiazol-2yl)
-2,5-diphenyltetrazolium bromide (MTT), 1,1-Dioctade-
cyl −3,3,3,3-tetramethylindodicarbocyanine (DiD), were
purchased from Keygen Biotech (Nanjing, China). FITC-
dextran (70 kDa) was purchased from TdB Consultancy
(Ferndown, UK). Dialysis cassettes (3500 Da) were
purchased from Viskase Companies (Houston, USA).
1 × PBS and 10 × PBS (pH 7.4) were purchased from
HyClone (USA), fetal bovine serum (FBS), penicillin
(10 kU/ml), streptomycin (10 μg/ml) (Penicillin-Strepto-
mycin Solution, 100×), 0.25% Trypsin-EDTA (1×), and
Gibco Dulbecco’s Modified Eagle’s Medium (DMEM)
were obtained from Invitrogen (USA). The dialysis tube
(width is 10 mm, molecular cut-off is 3500 Da) was
purchased from Viskase (USA).
Animals and Ethics
The Sprague Dawley rats, 8 weeks of age, were pur-
chased from the Experimental Animal Center of South-
ern Medical University of China (SCXK (Guangdong)
2012–0015) and were raised under specific pathogen-
free (SPF) condition in the Animal Center of Guangdong
Pharmaceutical University. The animal experiments in-
volved in present study were consistent with the guide-
lines set by the National Institutes of Health and were
approved by the Guangdong Experimental Animal Ethics
Committee.
Cells
The human umbilical vein cell line, EA.hy926, was
established by fusing primary human umbilical vein cells
with a thioguanine-resistant clone of A549 by exposure
to polyethylene glycol (PEG). The EA.hy926 cells used in
present study were donated by professor Li Ming of the
Foundation College of Guangdong Pharmaceutical
University.
HPLC Analysis Method
HPLC method was established by our lab and was used
for quantitative determination of STS. The experiment
was performed with a Shiseido-ODS C18 column (4.6 ×
150 mm); the mobile phase was consisted of methanol
and phosphate buffer (pH 3.5) (60:40 v/v); the flow rate
was 1 ml/min, and the UV detected wavelength was
271 nm. The temperature of column heater was main-
tained at 40 °C, and 20 μl sample solution was injected
for analysis. The limit of detection (LOD) of STS by
HPLC method was 0.02 μg/ml, and the limit of quantita-
tion (LOQ) was 0.06 μg/ml.
Fig. 1 Molecular structure of Sodium Tanshinone IIA sulfonate (STS)
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Preparation of STS-Nano-RBCs
STS-Nano-RBCs were prepared with the method re-
ported previously [14]. To prepare erythrocyte ghosts,
firstly, blood collected from SD rat put into tube with
heparin sodium. Then centrifuged to discard serum and
buffy coat, washed RBC three times with 1 × PBS
(pH 7.4) carefully to obtain packed RBC. After that, 1
volume packed RBC was incubated with 4 volumes
hypotonic 0.1 × PBS at 4 °C for 15 min to obtain
erythrocyte ghosts. The erythrocyte ghosts were centri-
fuged at 2000 rpm for 10 min and washed 3 times with
0.1 × PBS until the supernatant was colorless.
To prepare STS-Nano-RBCs, 1 volume STS (dissolved
in 0.1 × PBS) is added into the erythrocyte ghosts and is
incubated at 4 °C for 1 h with constant shaking by table
concentrator to load STS. Subsequently, 10 × PBS was
added to reseal the erythrocyte ghosts at 4 °C for 1 h.
The resealed erythrocyte ghosts were washed three times
and were resuspended in 1 × PBS. The particle size of
drug loaded erythrocyte ghosts was reduced with extru-
sion method. The erythrocyte ghosts contained STS
were extruded 21 cycles by the extruder (ATS engineer-
ing Canada) with different size of Nuclepore Track-
Etched Membrane (800, 400, and 200 nm). The free STS
was removed by ultrafiltration using Amicon Ultra-4
Centrifugal Filter at 5000 rpm for 30 min and was
washed with 1 × PBS to obtain the final STS-Nano-RBC
system.
In order to screen the optimal drug loading condi-
tions, different influence factors were investigated
including the STS concentration (0.2–2.5 mg/ml), load-
ing temperature (4 and 37 °C), loading volume ratio
(1:2–3:1), osmotic pressure (0.1 × PBS and 0.3 × PBS) as
well as STS loading time.
Characterization of STS-Nano-RBCs
Morphology
To test whether the erythrocyte external aqueous phase
could enter into the internal phase when erythrocyte
ghosts sealing in hyperosmotic solution, two different
fluorescent dyes were used for observation with fluores-
cence microscope (Carl Zeiss Jena, Germany). Red fluor-
escent dye DiD (10 μg/ml) and green fluorescent dye
FITC-dextran (70 kDa, 100 μg/ml) were incubated with
erythrocyte ghosts for 30 min to stain the membrane
and cytoplasm, respectively. The structure of STS-Nano-
RBCs was examined with a transmission electron micro-
scope. A drop of the sample solution was deposited onto
a glow-discharged carbon-coated grid. 5 min later, the
grid was rinsed with 10 drops of distilled water. A drop
of 1% uranyl acetate stain was added to the grid. The
grid was subsequently dried and visualized under a
HITACHI H-7650 microscope.
Particle Size and Zeta Potential
Beckman Coulter (LS13320, USA) was employed to
measure the particle size, size distribution, and surface
zeta-potential of STS-Nano-RBCs. The test sample was
prepared by diluting STS-Nano-RBCs with 1 × PBS into
proper concentration, and the tests were performed in
triplicate at room temperature.
Protein Content
To investigate the content of membrane protein in
erythrocyte and the STS-Nano-RBCs, red blood cell lysis
buffer was used to lyses the test samples and was ex-
tracted the total protein. SDS-PAGE method was used
to analyze the type of proteins. In short, erythrocyte and
STS-Nano-RBCs were prepared in SDS sample buffer.
The samples were then ran on a polyacrylamide gel elec-
trophoresis apparatus (BioRad, USA) at 100 V for 2 h.
Finally, the gel was stained with kaumas blue for 1 h
then was visualized using electrophoretic imaging system
(Aplegen Omega Lum G, USA).
STS Loading Efficiency Assay
Drug concentration of STS-Nano-RBCs system was
calculated with HPLC method. 50 μl STS-loaded nano-
RBCs were added into 3950 μl RBC lysis buffer. The test
samples were vortexed for 3 min, collected the lysis
solution 200 μl, added 2 ml methanol to extract STS,
and then centrifuged at 10000 rpm for 10 min, and 20 μl
supernatant was taken to analyze the STS content with
HPLC method (Hitachi Chromaster with 5110 pump,
5210 Autosampler, 5310 Column Oven, 5410 UV
detector) described above. Drug loading efficiency (LE%)
was measured with Eq. 1.
LE% ¼ Min=Mtotal  100% ð1Þ
Where, Min = the entrapment amount of STS in STS-
Nano-RBCs, Mtotal = the total amount of STS in STS-
Nano-RBCs.
Stability
The centrifugal stability of STS-Nano-RBCs was
assessed by centrifuging samples 10 min with different
speed (2000–12000 rpm). The turbulence stability of
STS-Nano-RBCs was also evaluated. In short, STS-
Nano-RBC was passed through a 4.5-gauge needle with
the flow rate of 10 ml/min, which was comparable with
the blood flow rate in vivo. The number of passes was
varied (10–30 times). Next, 10 K MWCO Amicon Ultra-
4 Centrifugal Filters were used to isolate free STS for
HPLC analysis. STS leakage rate was used as the index
to evaluate the system stability. Samples were stored at
4 °C for 21 days to investigate its storage stability, and at
given time point, indexes including appearance, drug
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leakage rate, particle size, and zeta potential were used
to evaluate the short-term stability of STS-Nano-RBCs.
In Vitro Release
The drug release behavior of STS-Nano-RBCs system
was evaluated with dialysis method in PBS (pH7.4) at
37 °C. 1 ml concentrated STS-Nano-RBCs was placed
into dialysis tube and immersed in 250 ml PBS. The dia-
lysis tube is 10 mm wide, and the molecular cut-off is
3500 Da. At each given time point, 1 ml released solu-
tion were collected and were replenished with equal
volume of PBS solution. For comparison, the release of
STS injection was also tested. All collected solution was
analyzed with HPLC method described before.
In Vivo Pharmacokinetics and Biodistribution Study
Pharmacokinetic characteristics of STS-Nano-RBCs
were conducted in adult SD rats. 12 SD rats were
divided into 2 groups, and test samples were intraven-
ously injected through rat tail vein with the dose of
5 mg/kg; the concentration of STS-Nano-RBC and STS
was 1.1 mg/ml. At each time points, the blood was col-
lected and centrifuged (2000 rpm for 10 min) to separate
the plasma. After that, 50 μl ethyl p-hydroxybenzoate
(1 μg/ml) and 1 ml acetonitrile were added into plasma
to extract STS. The mixture was vortex-mixed for 1 min
followed by centrifugation at 10000 rpm for 10 min. The
supernatant was evaporated under nitrogen atmosphere
condition and was redissolved with 200 μl mobile phase
before HPLC assay. The pharmacokinetic parameters
were calculated from the plasma concentrations of STS
with DAS2.0 software system. The pharmacokinetic
parameters estimated were maximum plasma concentra-
tion (Cmax), half-life (T1/2), the area under the plasma
concentration-time curve (AUC), and the mean resi-
dence time (MRT).
Next, we investigated the tissue distribution of STS-
Nano-RBC in SD rats to further evaluate its potential as
a delivery vehicle. We performed the biodistribution
study on 8 week-old SD rats (190–210 g, n = 12 per
group, half male, half female). SD rats were injected
STS-Nano-RBC or STS via tail vein, each rat was
injected with approximately 1.0 mg of STS injection or
STS-Nano-RBC. At each time point (12, 24, and 36 h)
post-injection of drug, blood was collected from the rat
eye vein plexus, four rats of each group were euthanized,
and their organs (hearts, livers, spleen, lungs, kidney)
were extracted and weighed. STS content in each group
was measured with HPLC method described before.
Cell Viability
MTT assay was conducted to identify the biocompatibil-
ity of STS-Nano-RBCs. EA.hy926 cell was seeded at the
density of 10000 cells per well in 96-well plate and with
100 μl DMEM. When 80% cells confluence was
observed, the growth media were replaced with equal
volume of test samples (STS, Nano-RBCs and STS-
Nano-RBCs, all dissolved in DMEM) with various con-
centrations for 24 h. Then, the media were refreshed
and were incubated with 20 μl MTT (5 mg/ml in PBS)
for another 4 h. Finally, the culture medium was re-
moved, 100 μl of DMSO was added, and the absorbance
Fig. 2 Schematic illustration of STS-Nano-RBCs preparation process
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was measured at 570 nm with a microplate reader
(BioRad, USA).
Protective Effect on Oxidative Stress-Impaired Cell
In order to study the repairing effect of STS-Nano-RBC on
oxidative stress impairs EA.hy926 cell, we adopted the
method published before [26]. In short, an oxidative stress-
impaired model was established with 750 μM H2O2 to
evaluate the protective and to repair effect of STS-Nano-
RBCs on oxidative stress-impaired cell. For nitric oxide
(NO), superoxide dismutase (SOD) and MDA assay,
EA.hy926 cells were seeded in 96-well plate with suitable
density. When 80% cell confluence was observed, the
growth media was replaced with 100 μl H2O2 (750 μM)
and was incubated for 12 h. Then the media was replaced
with various concentration of STS-Nano-RBC. 12 h later,
the supernatant (or cell lysis solution) was collected and an-
alyzed with Nitric Oxide Assay Kit, Total Superoxide Dis-
mutase Assay Kit, and Lipid Peroxidation MDA Assay Kit.
The repair efficiency of STS-Nano-RBCs was also observed
with fluorescence microscope.
Statistical Analysis
All experimental data in this study were shown as
mean ± standard deviation (SD). Statistical compari-
sons were calculated by using Student’s t test, p
values of <0.05 was taken to indicate statistical
difference.
Fig. 3 Fluorescent images of erythrocyte ghosts stained with the DiD (red) and FITC-dextran (green) and merged image (a); in bright field (b)
Fig. 4 a Membrane proteins retention of erythrocyte ghosts and STS-Nano-RBCs. b TEM image of STS-Nano-RBCs. c The particle size distribution
of STS-Nano-RBCs
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Results and Discussion
Preparation and Characterization of STS-Nano-RBCs
Nowadays, nanoparticle derived from erythrocyte has
widely attracted researchers’ attention due to its strong
biocompatibility and good inherent biodegradation in
vivo. In present study, we developed a new drug carrier
system using nano-size erythrocyte ghosts to load water-
soluble drug STS for delivery. STS-Nano-RBCs were
prepared through three major steps (shown in Fig. 2):
preparing the erythrocyte ghost, loading STS into ghosts,
and reducing its particle size into nano scale. It is worth
noting that rat hemoglobin in 4 °C is not soluble and
undergoes gelling and precipitation, which has not
happened when human or other mammal RBCs were
used; the data in present study was unique for rat
RBCs.
In hypotonic conditions, the small pores of erythro-
cytes membrane will open, which result in the entry of
external aqueous phase and dissolved materials. This
phenomenon could be observed in Fig. 3. As can be
seen, the erythrocytes membrane could be stained by
DiD (red), and FITC-dextran (green) solution, which in-
dicated that STS, as a hydrophilic small-molecule API,
could be encapsulated into erythrocytes too, which was
consistent with previous reports [17, 18].
The particle size distribution of final STS-Nano-RBCs
was measured with DLS method and then visualized
using transmission electron microscopy. As shown in
Fig. 4, nano particles were spherical, and the average
diameter of STS-Nano-RBCs was around 156 nm with
PDI of 0.045, which indicated a relatively narrow and a
unified size distribution. The zeta-potential, caused by
Fig. 5 Optimization of STS loading. a Effect of osmotic pressure. b Effect of temperature. c Effect of volume ratio of STS to erythrocyte. d STS
loading before and after erythrocyte ghosts resealing. e Effect of STS concentration. The data are presented as mean ± SEM (n = 3), *, **, ***
indicate p < 0.05, <0.01, and <0.001, respectively
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negatively charged proteins on the membrane of STS-
Nano-RBCs was −2.34 mv, and it was helpful to keep
the system stable due to electrostatic forces.
One of the most important advantages to use erythro-
cytes as a drug delivery system is that the functional
components contain immunosuppressive proteins on
erythrocyte membranes, which could inhibit macrophage
uptake and therefore prolonged the circulation time
[27]. As shown in Fig. 4, SDS-PAGE analysis result re-
vealed that in both samples, erythrocyte ghosts contain
all major protein fractions: α-spectrin, β-spectrin, actin,
glyceraldehyde-6-phosphate dehydrogenase, stomatin-
tropomyosin, and peroxiredoxin and reduced globin
chains. However, the result also revealed that several
major bands of protein color in Nano-RBC group was
weaker than in RBC group, which means the preparation
process might not cause the loss of protein species, but
could cause the loss of some protein content.
To optimize the STS-Nano-RBCs preparation process,
several influences were investigated in this study. As
shown in Fig. 5, lower hypotonic solution (0.1 × PBS)
could effectively load STS into erythrocyte ghosts, and
the drug loading efficiency was 39.7%, which is higher
than that obtained in 0.3 × PBS. This result was consist-
ent with previous study, which proved that decreased
osmolarity could result in the creation of more pores in
the membranes, allowing the entry of water and dis-
solved materials [17]. Temperature is also an important
parameter that could influence drug loading efficiency.
As can be seen in Fig. 5, STS loading rate at 4 °C was
higher than 37 °C, which might be caused by mobility of
membrane phospholipids and long time pores open in
low temperature. It is worth noting that STS loading rate
was increased with the increase of STS concentration,
which was ranged from 0.2 to 1.8 mg/ml and reached to
equilibrium when STS concentration exceeded 2.0 mg/
ml. The optimal volume ratio of STS solution to
erythrocyte ghosts was 2:1, and higher loading efficiency
could be obtained when STS was added before erythro-
cyte ghosts resealing.
Stability of STS-Nano-RBCs
Formulation stability was of great importance for the
preparation and application of nano carrier systems. In
the present study, centrifugation and turbulence stability
were used to assess the stability of STS-Nano-RBCs. The
result, as shown in Fig. 6a, revealed that STS leakage
rate was increased with centrifugation speed. When the
centrifugation speed was 10000 rpm, 7.1% of STS was
moved from internal to external water phase. For turbu-
lence stability, the result was shown in Fig. 6b, when the
number of passes increased to 30 times, the leakage rate
Fig. 6 In vitro stability of STS-Nano-RBCs. a Centrifugation stability. b Turbulence stability. c Hemolysis test. d The stability of Nano-RBCs and
STS-Nano-RBCs in PBS at 4 °C within 21 days. The data are presented as mean ± SEM (n = 3)
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of STS was just 1.96%, which indicated that STS-Nano-
RBCs could withstand the impact of blood flow in vivo.
When STS-Nano-RBCs were administrated intraven-
ously, it could be diluted and interacted with blood cells.
The formulations should keep stable with high dilution
ratio and could not cause hemolytic reaction. Here, the
potential interaction of STS-Nano-RBCs with the blood
cells was measured using hemolysis index. The data
showed that compared with 100% hemolysis caused
by water, STS-Nano-RBCs caused minimal hemolysis
(As shown in Fig. 6c). The long-term stability of STS-
Nano-RBCs was also investigated by testing the
indexes including appearance, particle size, zeta po-
tential, and entrapment efficiency within 21 days, as
shown in Fig. 6d, little particles aggregation was
found. The average diameter of STS-Nano-RBCs was
increased slightly from 160.2 to 174.4 nm, and the
surface potential could maintain negatively charged
(Table 1). STS entrapment efficiency was about 40%
during test period, which proved that STS-Nano-RBC
has good storage stability.
In Vitro and In Vivo Drug Release and In Vivo
Biodistribution
To assess the release characteristic, dialysis method was
used to investigate the STS release from STS-Nano-
RBCs in PBS solution at 37 °C. STS-Nano-RBCs group
showed sustainable release compared with STS injection.
As shown in Fig. 7a, STS injection presents typical fast
drug release behavior, within 6 h almost 97% STS could
be tested outside the dialysis tube. On the contrary,
STS-loaded Nano-RBCs showed sustained drug release
property in 48 h with the mean release rate of 1.98% per
hour, which was much slower than STS injection
(16.67% per hour).
When two formulations were administrated into SD
rats, as shown in Fig. 7b and Table 2, the result indicated
that compared with STS injection, using Nano-RBCs as
drug delivery system could prolong the drug release
time. In addition, Cmax of STS-Nano-RBC group and
STS injection group were 4.053 and 4.386 μg/ml, re-
spectively. Compared with STS injection group, half-life
(t1/2) of STS-Nano-RBC group increased from 2.59 to
6.92 h, and the mean residence time (MRT) increased
from 2.23 to 8.14 h. Drug concentration could be de-
tected after 36 h in STS-Nano-RBCs group, and the area
Fig. 7 In vitro release profile of STS-Nano-RBCs in PBS solution at 37 °C (a). b In vivo release profile of STS-Nano-RBCs in rats. c Biodistribution of
STS-Nano-RBC and STS injection. After intravenously injecting STS-Nano-RBC and STS into SD rats, the organs at each time point were collected
(12, 24, 48 h respectively), were homogenized, and were quantified for STS content. The data is presented as mean ± SEM (n = 6)
Table 1 The parameters of storage stability of STS-Nano-RBCs






0 40.1 −2.17 160.2 ± 4.5 0.047
7 39.8 −2.18 163.2 ± 5.7 0.047
14 39.6 −2.22 166.9 ± 3.3 0.051
21 39.5 −2.23 174.4 ± 3.4 0.056
The data are presented as mean ± SEM (n = 3)
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under the drug concentration-time curve was 19.69 μg/
ml · h, which indicated that STS-Nano-RBCs could
achieve sustained release. The release equation of STS-
Nano-RBC group was shown as Eq. 2, and the model
followed by STS-Nano-RBC was two-compartment
model.
C ¼ Ae‐αt þ Be‐βt ð2Þ
Where A = 2.423, B = 1.687, α = 0.856, β = 0.093.
Subsequently, we used SD rats to conduct the in vivo
biodistribution study. Figure 7c, d showed the STS con-
tent per gram of tissue, at 12 h after the injection, STS-
Nano-RBC showed hepatic and splenic uptake of 7.5
and 6.1 μg/g tissue, respectively, as compared to 6.4 and
5.2 μg/g tissue by STS injection. After accounting for
the tissue mass, it can be observed that with the injec-
tion time extended, STS-Nano-RBC observed in the liver
and spleen was increased, while in blood was de-
creased. Liver and spleen, as the two primary organs
of RES, contained the highest amount of STS-Nano-
RBCs, which also explained the fast blood elimination
of STS-Nano-RBC.
It is well known that the cycle time of erythrocyte in
rats is about 1 month, compared with autologous RBC,
the sustained release effect of STS-Nano-RBC was quite
limited. Combined with Fig. 4, it can be speculated that
the surface protein of erythrocyte, not only the protein
species but also the content, played an important role
on its cycle time. The surface glycoproteins of erythro-
cyte, such as CD47, as the signal molecule, could protect
RBCs from damage and elimination from body by
inhibiting the phagocytosis of macrophage through bind-
ing to SIRPα. Loss or just decrease of surface glycopro-
teins of erythrocyte, such as CD47, could inhibit the “do
not eat me” signal, which will cause STS-Nano-RBC to
be phagocytosed by macrophage [28]. Besides, Nano-
RBC, as the derivative of RBC, destructed the integrity
of mother cell, and the process of drug encapsulation
typically require multistep manipulations involving cell
isolation, incubations for several times, and washings,
which could harm the cell membrane and thus lead to
transposition of PS from the inner leaflet of the plasma
membrane to the RBC surface, which might accelerate
elimination of Nano-RBC in rats [29]. In addition, the
effect of polymeric nanoparticles on biocompatibility of
carrier erythrocyte has been investigated before; the re-
sult indicated that non-covalent adsorption of model
NPs (200 nm) to mouse and human RBC could affect
their sensitivity to osmotic stress, low level shear stress,
vigorous mechanical insult, and agglutination. Although
the result showed non-covalent adsorption of model
NPs to mouse and human RBC is not detrimental at
ratios of and below NP/RBC 200:1, it inspired us to as-
sume that whether Nano-RBC attached on RBC in rats
increases the RBC susceptibility to complement-
mediated lysis [30].
Cell Viability Assay
In order to select an appropriate concentration of H2O2
to build oxidative stress-impaired cell model, incubated
cells with different concentration of H2O2 for 12 h then
determined cell vitality with MTT method, as shown in
Fig. 8a, when H2O2 concentration was 700 μM, the cell
vitality was 74.77%, when H2O2 concentration was
800 μM, the cell vitality was 71.51%. In the present
study, we choose 750 μM H2O2 to build oxidative stress-
impaired cell model.
Application safety is a prerequisite for drug delivery
system, and here, the cell cytotoxicity was tested to
evaluate the biocompatibility of STS-Nano-RBCs.
EA.hy926 cells were chosen to assess the cell viability of
Table 2 Pharmacokinetics parameters calculated by DAS2.0
software
Cmax (μg/ml) T1/2 (h) AUC0−∞ (μg/ml · h) MRT (h)
STS 4.386 2.591 3.394 2.232
STS-Nano-RBC 4.053 6.917 19.698 8.141
Cmax maximum plasma concentration (μg/ml), T1/2 half-life of STS in plasma (h),
AUC0−∞ area under the curve (μg/ml · h), MRT mean retention time (h)
Fig. 8 a Cell viability of H2O2 in EA.hy926 cells. b Cell viability of STS injection, Nano-RBCs and STS-Nano-RBCs in EA.hy926 cells. The data are
presented as mean ± SEM (n = 6)
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STS-Nano-RBC with MTT method. As shown in Fig. 8b,
the concentration of STS-Nano-RBCs was ranged from
10 to 500 μg/ml. The MTT results indicated Nano-
RBCs showed little cytotoxicity to EA.hy926 cells. Cell
viability of both STS injection group and STS-Nano-
RBC group were decreased with the increase of STS
concentration. It was worth noting that when the con-
centration of STS was higher than or equal to 100 μg/
ml, STS-Nano-RBCs group showed more cytotoxicity
than STS group. This might be due to the difference of
STS concentration in cells at a given time. It is well
known that the way in which small-molecule weight
drug and nanoparticles enter cells is different, which
might cause different concentration of STS at a given
time and thus result in different cell viability. Since cell
survival rate was less than 50% when STS-Nano-RBC
concentration was greater than or equal to 200 μg/ml,
we selected 10–150 μg/ml as the concentration range to
examine the protection of STS against oxidative stress
injury cells.
Repairing Effect of STS-Nano-RBCs on Oxidative Stress Im-
pairs EA.hy926 cell
Reactive oxygen species (ROS), including hydrogen per-
oxide (H2O2), hydroxyl (OH
−), nitric oxide (NO), and
oxygen-free radical (O2−), are involved in multiple
physiological and pathological reactions [31]. Excessive
ROS can lead to cell apoptosis, and numerous studies
have revealed that ROS played an important role in oxi-
dative stress [32, 33]. Under the stimulation of cell-
injured signals and inflammatory mediators, the endo-
thelial cells will produce ROS in the intracellular com-
partment [34]. Since the redox homeostasis is the key to
maintain normal cells physiological activity [35], exces-
sive ROS will be removed from cell by enzymatic or
non-enzymatic reactions. Superoxide dismutase (SOD),
used to clean out the extra ROS, could maintain internal
balance, and its concentration has a positive correlation
with ROS level inside the cell [36]. ROS could also cause
phospholipids peroxidation of polyunsaturated fatty
acids on the cell membrane, and further disorder the
uniform structure of the cell membrane. Malondialde-
hyde (MDA), as the final product of lipid peroxidation,
is believed to reflect the phospholipids peroxidation de-
gree [37, 38]. As shown in Fig. 9, the SOD level was
raised with the increase of STS concentration. When
STS concentration was 80 μg/ml or higher, STS-Nano-
RBCs group showed higher SOD level compared with
STS injection group. NO, as an effective vasodilator
Fig. 9 Protective effect of STS-Nano-RBC group and STS injection
group on oxidative injured EA.hy926 cells by detecting the content
of SOD (a), NO (b), and MDA (c). The data are presented as
mean ± SEM (n = 6)
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molecule, could improve the blood flow of the ischemia
reperfusion and could regulate the recovery of damaged
endothelial cells. When STS concentration was 80 μg/ml
or higher than 100 μg/ml, higher content of NO could
be detected in STS-Nano-RBCs group than that in STS
injection group. Similar results could be seen in Fig. 10
that cells treated with STS-Nano-RBCs could remove
more ROS and cells therefore presented weak green
fluorescence (Fig. 10 (B-1)). However, positive group
showed strong green fluorescence, which means ROS
level was higher. The result demonstrated that STS-
Nano-RBCs showed better capability of repair oxidative
stress-impaired endothelial cells. Although STS-Nano-
RBC group showed a better repair effect at the concen-
trations of 80–150 μg/ml, there was no significant
difference in the repair effect of the two groups at low
concentrations (10–40 μg/ml). This may be due to the
inability to reach the repair threshold when the STS
concentration is lower than or equal to 40 μg/ml. The
STS-Nano-RBC group showed a better repair effect
when the STS concentration was or higher than
80 μg/ml, probably because the Nano-RBC changed
the way STS entered the cell, which caused different
STS concentration in cells, and then showed a better
repair effect. In conclusion, further studies on how
Nano-RBCs improve STS efficacy require experimen-
tal validation.
Conclusions
In this study, we developed a drug carrier system of
nano erythrocyte ghosts to deliver water-soluble drug
STS and to investigate its biological characteristics. STS
loaded into nano erythrocyte ghosts was found to exert
several benefits including good stability, sustained drug
releasing behavior, as well as bioavailability improve-
ment. It could also extend in vivo circulation time. Based
on the pharmacological experiment, it is evidence that
STS-loaded nano erythrocyte ghosts could upgrade the
repairing effect of damaged endothelial cells and can
serve as a drug delivery system to deliver STS.
Fig. 10 Fluorescent images of oxidative damaged EA.hy926 cells observed using H2DCFDA probe. a The positive control group. STS-Nano-RBCs
repairing group (b); STS repairing group (c) and the negative control group (d); 1 = 4×, 2 = 10×, 3 = 40×
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